Basel Medical Group Ltd (BMGL)
NASDAQ: BMGL · Real-Time Price · USD
0.6840
-1.2460 (-64.56%)
At close: Nov 11, 2026, 4:00 PM EST
0.6834
-0.0006 (-0.09%)
After-hours: Nov 11, 2026, 7:59 PM EST

Basel Medical Group Income Statement

Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Operating Revenue
16.4411.3210.059.710.66
Other Revenue
5.070.04-0.05-
21.5111.3510.059.7510.66
Revenue Growth
89.45%12.97%3.12%-8.55%-
Cost of Revenue
13.178.955.895.582.72
Gross Profit
8.342.44.164.167.94
Selling, General & Admin
0.010.1401.055.78
Other Operating Expenses
5.233.221.440.55-0.31
Operating Expenses
9.134.551.972.165.48
Operating Income
-0.79-2.142.222.46
Interest Expense
-0.46-0.2-0.18-0.24-0.32
Interest & Investment Income
-0.08-0.30.25
Other Non Operating Income (Expenses)
-1.560.390.07-
EBT Excluding Unusual Items
-1.25-0.72.42.132.39
Impairment of Goodwill
--10.35---
Pretax Income
-1.25-11.052.42.132.39
Income Tax Expense
0.18-0.420.330.350.41
Earnings From Continuing Operations
-1.43-10.642.071.781.98
Minority Interest in Earnings
0.680---
Net Income
-0.75-10.642.071.781.98
Net Income to Common
-0.75-10.642.071.781.98
Net Income Growth
--16.23%-9.84%-
Shares Outstanding (Basic)
22111
Shares Outstanding (Diluted)
22111
Shares Change
1.06%15.60%---
EPS (Basic)
-0.47-6.791.531.321.46
EPS (Diluted)
-0.78-6.791.531.321.46
EPS Growth
--16.23%-9.84%-

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22
Free Cash Flow
-0.88-4.62.52.592.7
Free Cash Flow Per Share
-0.56-2.941.851.922.00
Gross Margin
38.77%21.18%41.43%42.71%74.48%
Operating Margin
-3.67%-18.85%21.84%20.55%23.09%
Profit Margin
-3.48%-93.67%20.62%18.30%18.56%
Free Cash Flow Margin
-4.11%-40.52%24.89%26.61%25.37%
EBITDA
-0.44-2.032.232.032.48
EBITDA Margin
-2.04%-17.91%22.14%20.86%23.30%
D&A For EBITDA
0.350.110.030.030.02
EBIT
-0.79-2.142.222.46
EBIT Margin
-3.67%-18.85%21.84%20.55%23.09%
Effective Tax Rate
--13.80%16.34%17.12%
SEC Filings: 10-K · 10-Q